Comments on “Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial”

Martin Schlumberger


Patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that is radioactive iodine (RAI)- refractory and progressive have a poor prognosis due to the lack of effective treatment options. Several phase 2 trials have shown that some tyrosine kinase inhibitors with antiangiogenic effects are able to induce tumor responses in some patients, but there is yet no demonstration in a phase 3 trial that they may prolong progression free survival.